Investigating a new treatment for dementia with Lewy bodies
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)
This study is looking at how well a new oral medication called neflamapimod can help improve thinking and movement problems in people with mild-to-moderate dementia with Lewy bodies, a condition that currently has no approved treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Eip Pharma, INC. NIH-funded |
| Lab location | 1 site (Boston, UNITED STATES) |
| Project ID | NIH-11019686 on NIH RePORTER |
What this research studies
This research focuses on evaluating the effectiveness of neflamapimod, a specific inhibitor targeting a key enzyme involved in neurodegeneration, in patients with mild-to-moderate dementia with Lewy bodies (DLB). The study aims to assess how this oral medication can improve cognitive and motor symptoms associated with DLB, which currently has no approved treatments. Participants will be monitored for changes in their symptoms and overall quality of life throughout the trial period. The research is designed to provide insights into the potential of neflamapimod to address the underlying causes of DLB.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with mild-to-moderate dementia with Lewy bodies.
Not a fit: Patients with other types of dementia or those with advanced stages of dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that significantly alleviates symptoms and improves the quality of life for patients with dementia with Lewy bodies.
How similar studies have performed: Previous studies have shown promise with similar approaches targeting neurodegenerative mechanisms, suggesting potential for success in this research.
Where this research is happening
Boston, UNITED STATES
- Eip Pharma, INC. — Boston, United States (Active)
Researchers
- Principal investigator: Alam, John — Eip Pharma, INC.
- Study coordinator: Alam, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.